Source Count: 13 | Weighted Score: 32 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: March 14, 2026
Keywords: endocrinology, hormones, insulin, diabetes, thyroid, pituitary, adrenal, endocrine disruptors, BPA, cortisol, testosterone, estrogen, pancreas, islets of Langerhans, hypothalamus, feedback loops, metabolic syndrome
Category Tags: medicine-healing, clinical-endocrinology, hormone-discovery, diabetes-history, endocrine-disruption
Cross-References: X_1_02 — Ayurveda & Indian Medicine · X_1_15 — Greek & Roman Medicine · X_2_15 — Regenerative Medicine & Stem Cells · X_3_02 — Vaccination & Immunology · X_3_03 — Epidemic & Pandemic History · X_3_08 — Cancer Research History · X_4_02 — Medical Ethics · X_5_09 — Pharmacology

QUICK SUMMARY

Endocrinology is the branch of medicine dealing with the endocrine system—a network of ductless glands that secrete hormones directly into the bloodstream to regulate metabolism, growth, reproduction, and homeostasis. The field emerged from Arnold Berthold's 1849 cockerel castration experiment, through the coining of the word "hormone" by William Bayliss and Ernest Starling in 1902, to the landmark isolation of insulin by Frederick Banting, Charles Best, John Macleod, and James Collip in 1921–1922. Major endocrine glands include the hypothalamus, pituitary, thyroid, parathyroid, adrenals, pancreas, and gonads. Endocrine disrupting chemicals (EDCs)—including BPA, phthalates, and PCBs—have emerged as a significant 21st-century public health concern, with the Endocrine Society warning they pose risks to reproduction, metabolism, and neurological development.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

The Endocrine System Architecture

KEY FINDING The human endocrine system consists of feedback loops mediated primarily through the hypothalamus and pituitary gland. Three critical axes govern systemic regulation:

• Hypothalamic–Pituitary–Thyroid (HPT) axis: TRH → TSH → T3/T4, regulating metabolic rate, body temperature, and cell growth
• Hypothalamic–Pituitary–Adrenal (HPA) axis: CRH → ACTH → cortisol, controlling stress response and immune function
• Hypothalamic–Pituitary–Gonadal (HPG) axis: GnRH → LH/FSH → sex hormones (testosterone, estrogen, progesterone)

Major endocrine glands include the pineal gland (melatonin), pituitary gland (growth hormone, ACTH, TSH, LH, FSH, prolactin), thyroid (T3, T4), parathyroid (PTH—calcium regulation), adrenal cortex (cortisol, aldosterone) and medulla (epinephrine, norepinephrine), pancreas (insulin, glucagon via islets of Langerhans), ovaries (estrogen, progesterone), and testes (testosterone).

Hormones are classified into three chemical classes: amines (catecholamines, thyroid hormones—derived from tyrosine), peptides and proteins (insulin, growth hormone, leptin), and steroids (cortisol, testosterone, estrogen—derived from cholesterol).

Discovery of Hormones and the Birth of Endocrinology

In 1849, Arnold Berthold in Göttingen demonstrated that castrated cockerels lost their combs, wattles, and masculine behaviour, but that transplanting testes back into the abdominal cavity restored normal development—the first experimental evidence of an internal secretion affecting distant tissues.

In 1889, Joseph von Mering and Oskar Minkowski excised the pancreas of a dog and observed that it rapidly developed diabetes mellitus symptoms (polyuria, glycosuria), establishing the pancreatic origin of glucose regulation.

In 1893, Édouard Laguesse proposed that the islet cells first described by Paul Langerhans in 1869 as "little heaps of cells" played a regulatory role in carbohydrate metabolism. In 1909, Belgian physician Jean de Meyer hypothesized these islets secrete a metabolic substance, naming it "insulin" from Latin insula ('island').

KEY FINDING In 1902, William Bayliss and Ernest Starling at University College London discovered secretin—the first identified hormone—and coined the term "hormone" (from Greek hormōn, 'to set in motion'). They demonstrated that acid instilled into the duodenum caused pancreatic secretion even after all nervous connections were severed, proving chemical (not neural) signalling.

The Insulin Revolution

KEY FINDING In 1921–1922, a team at the University of Toronto—Frederick Banting, Charles Best, John Macleod, and James Collip—isolated and purified pancreatic extract (insulin) for clinical use. On January 23, 1922, Leonard Thompson became the first diabetic patient successfully treated with Collip's purified insulin at Toronto General Hospital. Six more patients were treated by February 1922. In October 1923, Banting and Macleod received the Nobel Prize in Physiology or Medicine; they publicly shared the prize with Best and Collip, respectively.

Frederick Sanger determined the amino acid sequence of insulin—the first protein to have its structure determined—earning a Nobel Prize. Rosalyn Yalow and Solomon Berson developed the radioimmunoassay for insulin (1960), with Yalow receiving the 1977 Nobel Prize in Physiology or Medicine.

Type 1 and Type 2 diabetes were first distinguished by French researchers Apollinaire Bouchardat and E. Lancereux between 1850 and 1875 (as diabetes maigre and diabetes gras). The terms "type 1" and "type 2" were coined by Philip Hugh-Jones in 1955 while working in Jamaica, and revived by Andrew Cudworth in 1976 after discovering the link between type 1 diabetes and a specific genetic marker.

Neurohormones and Second Messengers

Otto Loewi in 1921 identified the first neurohormone by showing that stimulating the vagus nerve of a frog heart released a substance (later identified as acetylcholine) that could slow a second heart bathed in the same solution. Loewi received the Nobel Prize for this discovery.

Earl Sutherland in 1962 discovered the concept of second-messenger-mediated pathways by showing that norepinephrine acted on cell membrane receptors (not intracellularly) to produce cyclic AMP (cAMP), which activated phosphorylase in liver cells. Sutherland received the Nobel Prize for this groundbreaking work.

Ancient Roots of Endocrine Knowledge

Chinese practitioners were isolating sex and pituitary hormones from human urine by 200 BC, using methods including sublimation of steroid hormones and extraction with saponin from Gleditsia sinensis beans. Ayurvedic physicians Sushruta and Charaka (5th/6th century BC) first noted the sweet taste of diabetic urine (glycosuria) and distinguished what later became known as Type 1 and Type 2 diabetes, at least a thousand years before European descriptions.

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

Major Endocrine Diseases

Common endocrine disorders include:

• Diabetes mellitus: ~537 million adults worldwide (IDF, 2021); Type 1 (autoimmune destruction of beta cells) and Type 2 (insulin resistance/relative deficiency)
• Thyroid disease: Graves' disease (hyperthyroidism, described by Robert James Graves in 1835), Hashimoto's thyroiditis (autoimmune hypothyroidism)
• Addison's disease: adrenal insufficiency, first described by Thomas Addison in 1849
• Cushing's syndrome: hypercortisolism due to ACTH-secreting pituitary adenoma
• Acromegaly: excess growth hormone
• Metabolic syndrome: constellation of insulin resistance, obesity, hypertension, and dyslipidemia, identified by Gerald Reaven in 1988
• Polycystic ovary syndrome (PCOS): hormonal disorder affecting female reproductive function

Endocrine Disrupting Chemicals (EDCs)

The term "endocrine disruptor" was coined at the 1991 Wingspread Conference in Wisconsin. Theo Colborn et al. published a seminal paper in 1993 establishing that environmental chemicals disrupt endocrine system development, often with permanent effects.

Key classes of EDCs include:

• Bisphenol A (BPA): found in plastic bottles, food containers, and receipt paper; a known xenoestrogen linked to diabetes, obesity, reproductive problems, and neurological effects in laboratory animals. A 2011 cross-sectional study found BPA in 96% of pregnant US women. The FDA banned BPA from baby bottles in 2012 but maintained its use in other food packaging was safe
• Phthalates: found in soft toys, flooring, cosmetics, medical equipment; disrupt male reproductive development and insulin/glucagon signalling
• DDT: banned in most countries but still used as anti-malarial insecticide in Africa; interferes with female reproductive organ development
• Polychlorinated biphenyls (PCBs): worldwide production ban in 1977 following poisoning of thousands in Japan (Yushō disease, 1968) and Taiwan (Yu-cheng disease, 1979); toxic to liver and thyroid, increase diabetes risk
• Polybrominated diphenyl ethers (PBDEs): flame retardants with neurotoxic effects similar to PCBs; disrupt thyroid hormone balance; banned in the EU in 2006

The Endocrine Society released a 2009 scientific statement concluding that EDCs pose "a significant concern to public health," affecting reproduction, breast and prostate cancer, neuroendocrinology, thyroid function, metabolism, and cardiovascular health. The WHO and UNEP issued the most comprehensive report on EDCs in 2013, calling for more research.

Diethylstilbestrol (DES), a synthetic estrogen prescribed to up to 5 million pregnant women before its ban in the early 1970s, produced reproductive tract abnormalities and cancer in exposed offspring—providing a key case study in endocrine disruption.

Modern Developments

In 1980, Genentech developed biosynthetic human insulin using genetically engineered bacteria containing the human insulin gene. By 1996, insulin analogues with improved pharmacokinetic properties became available.

In 2005, a Type 2 diabetes drug derived from Gila monster venom (exendin-4 → exenatide) was approved by the FDA, triggering an insulin-releasing pathway through GLP-1 receptor agonism—now one of the most important diabetes drug classes (GLP-1 receptor agonists including semaglutide).

NPH long-acting insulin was developed by Novo Nordisk in the 1940s. Sulfonylureas were identified in 1942. Metformin was first marketed in France in 1979, not reaching the US until 1994.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

Low-Dose EDC Effects and Non-Monotonic Dose Responses

available evidence suggests that EDCs can exert adverse effects at much lower doses than traditional toxicological thresholds predict, following non-monotonic (U-shaped or inverted-U) dose-response curves. This challenges the classical toxicology assumption that "the dose makes the poison." Hormones naturally operate at part-per-billion concentrations, meaning even small exogenous exposures can disrupt function.

Economic Burden of EDC Exposure

Trasande et al. (2015) estimated the annual health costs from EDC exposure in the European Union at approximately €157 billion (~$209 billion), encompassing obesity, diabetes, reproductive disorders, and neurodevelopmental effects. These estimates remain controversial due to uncertainties in exposure-outcome attribution.

BPA-Free Products May Not Be Safer

A 2011 study found that some "BPA-free" plastic products released more endocrine-active chemicals than BPA-containing products. BPA substitutes such as Bisphenol S (BPS) and Bisphenol F (BPF) have been shown to be endocrine disruptors comparable to BPA, questioning whether regulatory "BPA-free" labelling meaningfully reduces exposure risk.

Body Temperature Decline and Thyroid Disruption

The long-term slow decline in average human body temperature observed since the beginning of the industrial revolution has been speculatively linked to disrupted thyroid hormone signalling from environmental EDC exposure, though causation has not been established.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

Humoral Theory as Endocrine Explanation

DEBUNKED Ancient Greek and Roman physicians including Hippocrates, Aristotle, and Galen employed humoral theory—balancing blood, phlegm, yellow bile, and black bile—as the dominant framework for understanding bodily regulation. While early anatomists identified most endocrine glands, the humoral approach persisted until the 19th century, when germ theory, physiology, and organ-based pathology displaced it. Humoral theory provided no mechanistic understanding of hormonal signalling.

FDA 2008 BPA Safety Assessment

DEBUNKED In August 2008, the FDA issued a draft reassessment declaring BPA safe for consumers. However, in October 2008, the FDA's own advisory Science Board concluded the assessment was "flawed" and had not proven BPA safe for formula-fed infants. In January 2010, the FDA acknowledged "some level of concern" regarding effects of BPA on brain and behaviour of fetuses, infants, and young children, effectively repudiating its earlier blanket reassurance.

Counter-Arguments & Criticisms

1. EDC dose-response controversy: Some toxicologists maintain that traditional dose-response models are adequate for assessing EDC risk and that low-dose effects observed in laboratory animals do not reliably predict human health outcomes at environmental exposure levels
2. BPA regulatory divide: The European Union has taken a more precautionary approach to BPA restriction than the United States. The CLARITY-BPA program (NIEHS/NTP/FDA) found no effect of chronic BPA exposure in rats, and the FDA considers currently authorized uses safe—contrasting with European bans
3. Insulin discovery priority: At least 400 researchers attempted pancreatic extracts before the Toronto group, including George Ludwig Zuelzer (1906–1908), Ernest Lyman Scott (1911–1912), Israel Kleiner (1915–1919), and Nicolae Paulescu (1916–1921, who applied for a Romanian patent on "pancréine"). The 1923 Nobel Prize attribution remains a subject of historical debate
4. Type 2 diabetes as lifestyle vs. endocrine disease: Whether Type 2 diabetes should be framed primarily as a metabolic-endocrine disorder or a lifestyle-related condition continues to shape prevention and treatment strategies

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Bayliss, William M.; Ernest H | 1902 | "The Mechanism of Pancreatic Secretion" | The Journal of Physiology | ∅ | 28.5::325–353 | Starling | ∅ | doi:10.1113/jphysiol.1902.sp000920 | ∅ | ∅ | ∅
2. Bliss, Michael | 2007 | ∅ | The Discovery of Insulin | ∅ | ∅ | 25th anniversary ed | ∅ | isbn:9780226058993 | ∅ | ∅ | Chicago: University of Chicago Press
3. Diamanti-Kandarakis, Evanthia, et al | 2009 | "Endocrine-Disrupting Chemicals: An Endocrine Society Scientific Statement" | Endocrine Reviews | ∅ | 30.4::293–342 | ∅ | ∅ | doi:10.1210/er.2009-0002 | ∅ | ∅ | ∅
4. Sutherland, Earl W | 1972 | "Studies on the Mechanism of Hormone Action" | Science | ∅ | 177.4047::401–408 | ∅ | ∅ | doi:10.1126/science.177.4047.401 | ∅ | ∅ | ∅
5. Karamanou, Marianna | 2016 | "Milestones in the History of Diabetes Mellitus: The Main Contributors" | World Journal of Diabetes | ∅ | 7.1::1–7 | ∅ | ∅ | doi:10.4239/wjd.v7.i1.1 | ∅ | ∅ | ∅
6. Polonsky, Kenneth S | 2012 | "The Past 200 Years in Diabetes" | New England Journal of Medicine | ∅ | 367.14::1332–1340 | ∅ | ∅ | doi:10.1056/NEJMra1110560 | ∅ | ∅ | ∅
7. Vandenberg, Laura N., et al | 2012 | "Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses" | Endocrine Reviews | ∅ | 33.3::378–455 | ∅ | ∅ | doi:10.1210/er.2011-1050 | ∅ | ∅ | ∅
8. Trasande, Leonardo, et al | 2015 | "Estimating Burden and Disease Costs of Exposure to Endocrine-Disrupting Chemicals in the European Union" | Journal of Clinical Endocrinology & Metabolism | ∅ | 100.4::1245–1255 | ∅ | ∅ | doi:10.1210/jc.2014-4324 | ∅ | ∅ | ∅
9. Nussey, Stephen; Saffron Whitehead | 2001 | ∅ | Endocrinology: An Integrated Approach | ∅ | ∅ | Oxford: Bios Scientific | ∅ | isbn:9781859962527 | ∅ | ∅ | ∅
10. Freeman, Eric R., David A | 2001 | "A Brief History of Testosterone" | Journal of Urology | ∅ | 165.2::371–373 | Bloom, and Edward J | ∅ | doi:10.1097/00005392-200102000-00004 | ∅ | ∅ | McGuire
11. Sanders, Lee J | 2002 | "From Thebes to Toronto and the 21st Century: An Incredible Journey" | Diabetes Spectrum | ∅ | 15.1::56–60 | ∅ | ∅ | doi:10.2337/diaspect.15.1.56 | ∅ | ∅ | ∅
12. Gardner, David; Dolores Shoback | 2017 | ∅ | Greenspan's Basic and Clinical Endocrinology | ∅ | ∅ | New York: McGraw-Hill | 10th | isbn:9781259589287 | ∅ | ∅ | ∅
13. Colborn, Theo, Frederick S. vom Saal; Ana M | 1993 | "Developmental Effects of Endocrine-Disrupting Chemicals in Wildlife and Humans" | Environmental Health Perspectives | ∅ | 101.5::378–384 | Soto | ∅ | doi:10.1289/ehp.93101378 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 14, 2026